Vaccine maker Adimmune Corp (國光生技) yesterday said it plans to start in August phase I clinical trials of its COVID-19 vaccine candidate, which effectively inhibited the growth of the novel coronavirus in preliminary animal tests last month.
Adimmune told a news conference in Taipei that it had designed and produced four prototypes of antigens to fight the virus based on its recombinant protein technology, and last month tested one prototype in a biosafety level 3 (BSL-3) lab at National Taiwan University (NTU).
After injecting the antigen into a few mice and seeing them generate antibodies, Adimmune extracted their plasma and placed it in another cell as well as the novel coronavirus to test the outcome, the company said.
Photo: Chien Hui-ju, Taipei Times
“The tests showed that the antibodies could inhibit the growth of the novel coronavirus and remained fully capable with a dilution of 1:640,” NTU Department of Clinical Laboratory Sciences and Medical Biotechnology professor Chang Sui-yuan (張淑媛) said.
The inhibition rate remained above 80 percent with a dilution of 1:1280, attesting to the strong effect of the vaccine candidate, Adimmune chairman Steve Chan (詹啟賢) said, adding that a flu vaccine is regarded as effective if its inhibition rate is higher than 80 percent with a dilution of 1:320.
The virus tested was from an isolated strain with the highest toxicity among NTU’s more than 20 isolated virus strains, Chang said.
“The tests gave us encouraging results and we feel confident. However, given that the novel coronavirus mutates, we need to run tests on more virus strains to see if the candidate will work against most of them,” she said.
The lab spent about one month setting up protocols and conducting tests, she added.
Adimmune does not know how long the vaccine candidate can protect humans from the virus, but would find out the answers in the clinical trials, Chan said.
The firm on Tuesday began the second stage of animal tests to see if the vaccine candidate would endanger mice and plans to complete the tests in October, he said.
While most vaccine developers have to wait for animal tests to be completed and for the results to be confirmed before moving on to human tests, Adimmune plans to expedite the process by applying to conduct human trials in August, Chan said.
Like other foreign regulators worldwide, Taiwan’s Food and Drug Administration has launched emergency use authorizations programs to speed up the development of a treatment for COVID-19, he said.
Adimmune has been included in the agency’s program and would be granted priority when applying for reviews or clinical trials, the company said.
After completing the animal tests’ interim analysis to make sure its candidate is safe, Adimmune would apply to conduct phase I clinical trials in August, and commence phase II and phase III trials in the first quarter next year, Chan said.
“We have to take some risks here for if the animal tests turn up negative, the phase I trial will have to stop,” he said.
The company’s goal is to start mass production of the vaccines in December if it gains approval of an emergency use authorization by the Taiwanese regulators, before gaining marketing approval next year, he said.
DIVIDED VIEWS: Although the Fed agreed on holding rates steady, some officials see no rate cuts for this year, while 10 policymakers foresee two or more cuts There are a lot of unknowns about the outlook for the economy and interest rates, but US Federal Reserve Chair Jerome Powell signaled at least one thing seems certain: Higher prices are coming. Fed policymakers voted unanimously to hold interest rates steady at a range of 4.25 percent to 4.50 percent for a fourth straight meeting on Wednesday, as they await clarity on whether tariffs would leave a one-time or more lasting mark on inflation. Powell said it is still unclear how much of the bill would fall on the shoulders of consumers, but he expects to learn more about tariffs
NOT JUSTIFIED: The bank’s governor said there would only be a rate cut if inflation falls below 1.5% and economic conditions deteriorate, which have not been detected The central bank yesterday kept its key interest rates unchanged for a fifth consecutive quarter, aligning with market expectations, while slightly lowering its inflation outlook amid signs of cooling price pressures. The move came after the US Federal Reserve held rates steady overnight, despite pressure from US President Donald Trump to cut borrowing costs. Central bank board members unanimously voted to maintain the discount rate at 2 percent, the secured loan rate at 2.375 percent and the overnight lending rate at 4.25 percent. “We consider the policy decision appropriate, although it suggests tightening leaning after factoring in slackening inflation and stable GDP growth,”
Meta Platforms Inc offered US$100 million bonuses to OpenAI employees in an unsuccessful bid to poach the ChatGPT maker’s talent and strengthen its own generative artificial intelligence (AI) teams, OpenAI CEO Sam Altman has said. Facebook’s parent company — a competitor of OpenAI — also offered “giant” annual salaries exceeding US$100 million to OpenAI staffers, Altman said in an interview on the Uncapped with Jack Altman podcast released on Tuesday. “It is crazy,” Sam Altman told his brother Jack in the interview. “I’m really happy that at least so far none of our best people have decided to take them
PLANS: MSI is also planning to upgrade its service center in the Netherlands Micro-Star International Co (MSI, 微星) yesterday said it plans to set up a server assembly line at its Poland service center this year at the earliest. The computer and peripherals manufacturer expects that the new server assembly line would shorten transportation times in shipments to European countries, a company spokesperson told the Taipei Times by telephone. MSI manufactures motherboards, graphics cards, notebook computers, servers, optical storage devices and communication devices. The company operates plants in Taiwan and China, and runs a global network of service centers. The company is also considering upgrading its service center in the Netherlands into a
RSS